北大医药董事长徐晰人被抓前，警方去集团厂区调查过！内部人士：集团资产被其处置，巨额资金去向不明

Core Viewpoint - The recent criminal detention of Xu Xiren, the chairman and president of Beijing University Pharmaceutical (000788.SZ), has plunged the company and its controlling entity, Southwest Synthetic Pharmaceutical Group, into a public relations crisis, raising concerns about management stability and employee welfare [2][12][40]. Group 1: Management Changes and Employee Sentiment - Xu Xiren's acquisition of Beijing University Pharmaceutical was marked by a symbolic purchase price of 1 yuan for 100% equity, which led to a significant drop of approximately 15% in the company's stock price within five trading days [8][9]. - Employee sentiment shifted from initial acceptance to growing dissatisfaction, particularly after the removal of holiday benefits and high-temperature subsidies, which had not occurred in previous years [9][11]. - The abrupt departure of several key executives, including the well-regarded former president Yuan Pingdong, has left employees uncertain about future operations and management effectiveness [11][12]. Group 2: Internal Conflicts and Investigations - Historical employee placement issues, stemming from past acquisitions, have remained unresolved, and Xu Xiren's management has failed to address these longstanding problems, leading to increased employee unrest [15][16]. - The situation escalated to the point where nearly a hundred retired employees protested against the company, citing unresolved housing and welfare issues [12][13]. - The police became involved following these protests, leading to Xu Xiren's detention on charges of embezzlement, with investigations focusing on financial operations and asset disposals under his management [21][22][24]. Group 3: Financial and Operational Implications - The company is facing significant financial challenges, including a potential revenue loss of approximately 600 million yuan (about 29.13% of recent audited revenue) due to the expiration of a key contract with Beijing University International Hospital [40]. - The third quarter results reflected these challenges, with a 47.95% year-on-year decline in revenue and an 18.04% decrease in net profit [40][41]. - The ongoing "de-BU" process, which involves severing ties with the Beijing University brand, has not progressed as planned, further complicating the company's operational landscape [40].